Use of the 40-Gene Expression Profile (40-GEP) Test in Medicare-Eligible Patients Diagnosed with Cutaneous Squamous Cell Carcinoma (cSCC) to Guide Adjuvant Radiation Therapy (ART) Decisions Leads to a Significant Reduction in Healthcare Costs . (2024). SKIN The Journal of Cutaneous Medicine, 8(1), s336. https://doi.org/10.25251/skin.8.supp.336